189 related articles for article (PubMed ID: 9669267)
41. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Chimienti M; Cullen MT; Casadei G
Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
[TBL] [Abstract][Full Text] [Related]
42. The Wrong Drug That Led to the Right Diagnosis.
Bergonti M; Assanelli E; Agostoni P
Circulation; 2019 Nov; 140(19):1601-1604. PubMed ID: 31682531
[No Abstract] [Full Text] [Related]
43. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Antman EM; Beamer AD; Cantillon C; McGowan N; Friedman PL
J Am Coll Cardiol; 1990 Mar; 15(3):698-707. PubMed ID: 2303641
[TBL] [Abstract][Full Text] [Related]
44. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
[TBL] [Abstract][Full Text] [Related]
45. Amiodarone versus sotalol for atrial fibrillation.
Zimetbaum PJ; Josephson ME
N Engl J Med; 2005 Aug; 353(6):627-30; author reply 627-30. PubMed ID: 16094764
[No Abstract] [Full Text] [Related]
46. [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study].
Bellandi F; Dabizzi RP; Niccoli L; Cantini F; Palchetti R
G Ital Cardiol; 1996 Apr; 26(4):379-90. PubMed ID: 8707022
[TBL] [Abstract][Full Text] [Related]
47. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
LaPointe NM; Pamer CA; Kramer JM
Pharmacotherapy; 2003 Oct; 23(10):1316-21. PubMed ID: 14594348
[TBL] [Abstract][Full Text] [Related]
48. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
Basta M; Klein GJ; Yee R; Krahn A; Lee J
Cardiol Clin; 1997 Nov; 15(4):587-97. PubMed ID: 9403162
[TBL] [Abstract][Full Text] [Related]
49. Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Manz M; Lüderitz B
Eur Heart J; 1993 Sep; 14 Suppl E():91-8. PubMed ID: 8223763
[TBL] [Abstract][Full Text] [Related]
50. Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis.
Wurdeman RL; Mooss AN; Mohiuddin SM; Lenz TL
Chest; 2002 Apr; 121(4):1203-10. PubMed ID: 11948054
[TBL] [Abstract][Full Text] [Related]
51. Current therapy for supraventricular tachycardia.
Haines DE; DiMarco JP
Curr Probl Cardiol; 1992 Jul; 17(7):411-77. PubMed ID: 1606844
[No Abstract] [Full Text] [Related]
52. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
[No Abstract] [Full Text] [Related]
53. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
Podrid PJ; Anderson JL
Am J Cardiol; 1996 Aug; 78(4):430-4. PubMed ID: 8752188
[TBL] [Abstract][Full Text] [Related]
54. [Combination anti-arrhythmia therapy].
Manz M; Jung W; Lüderitz B
Internist (Berl); 1993 May; 34(5):444-51. PubMed ID: 7685329
[No Abstract] [Full Text] [Related]
55. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter.
Tai CT; Chen SA; Chiang CE; Lee SH; Ueng KC; Wen ZC; Huang JL; Chen YJ; Yu WC; Feng AN; Chiou CW; Chang MS
Circulation; 1997 Oct; 96(8):2601-11. PubMed ID: 9355900
[TBL] [Abstract][Full Text] [Related]
56. Fetal atrial flutter: a case report and experience of sotalol treatment.
Wu TH; Huang LC; Ho M; Lee CC; Chiu TH; Hung YC
Taiwan J Obstet Gynecol; 2006 Mar; 45(1):79-82. PubMed ID: 17272217
[TBL] [Abstract][Full Text] [Related]
57. Cardioversion with sotalol in selected patients with vagally and adrenergically mediated paroxysmal atrial fibrillation.
Yeşil M; Bayata S; Postaci N; Yücel O; Aslan O
Angiology; 1999 Sep; 50(9):729-33. PubMed ID: 10496499
[TBL] [Abstract][Full Text] [Related]
58. Effect of SU 13197, a new antiarrhythmic agent, on atrial arrhythmias: preliminary study.
Dreifus LS; Lim HF; Rabbino MD; Watanabe Y
Am J Cardiol; 1968 Apr; 21(4):544-8. PubMed ID: 5645997
[No Abstract] [Full Text] [Related]
59. Interatrial conduction block with retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmias: influence of preventive antiarrhythmic treatment.
Bayés de Luna A; Oter MC; Guindo J
Int J Cardiol; 1989 Feb; 22(2):147-50. PubMed ID: 2914739
[TBL] [Abstract][Full Text] [Related]
60. [Experience with dl-sotalol in the treatment of supraventricular arrhythmia].
Trabulo M; Almeida M; Caires G; Mesquita A; Parreira L; Morgado F; Adragão P; Bonhorst D; Seabra-Gomes R
Rev Port Cardiol; 1996 Oct; 15(10):725-9, 696. PubMed ID: 9115766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
